Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.2.51 CHF
Change Today 0.00 / 0.00%
Volume 0.0
WBIO On Other Exchanges
As of 10:30 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

wockhardt bio ag-br (WBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/7/15 - SFr.3.46
52 Week Low
07/2/15 - SFr.2.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WOCKHARDT BIO AG-BR (WBIO)

Related News

No related news articles were found.

wockhardt bio ag-br (WBIO) Related Businessweek News

No Related Businessweek News Found

wockhardt bio ag-br (WBIO) Details

Wockhardt Bio AG, together with its subsidiaries, engages in the development, manufacture, and marketing of pharmaceutical and bio-pharmaceutical formulations primarily in the United States, the United Kingdom, Ireland, France, and Latin Americas. The company’s product portfolio consists of approximately 600 pharmaceutical products that are manufactured in various dosage strengths and forms utilizing immediate or sustained release, as well as injectable pharmaceutical products. Its products cover various therapeutic categories, including central nervous system agents, hormones and related agents, cardiovascular agents, anti-inflammatory drugs, anti-infective agents, respiratory agents, and other agents, such as gastrointestinal, dermatological, and biological (vaccines) agents. The company also exports generic pharmaceutical products to approximately 50 countries primarily to Europe and the Middle East. The company is based in Zug, Switzerland. Wockhardt Bio AG is a subsidiary of Wockhardt Limited.

wockhardt bio ag-br (WBIO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

wockhardt bio ag-br (WBIO) Key Developments

Forest Labs Sues Sun Pharma Global FZE, Teva Pharmaceuticals USA, Inc. and Wockhardt Bio AG for Infringement of NAMENDA XR Patents

Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. Said Friday that Forest, Merz Pharma GmbH & Co. KgaA and Adamas Pharmaceuticals, Inc. have jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for infringement of some or all of U.S. Patent Nos. 5,061,703; 8,039,009; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; and 8,598,233, which relate to Forest's NAMENDA XR product. Forest licenses the '703 patent, which expires in April 2015, from Merz, and the '209, '708, '379, '752, '085 and '233 patents, which expire in November 2025, from Adamas. Forest owns the '009 patent, which expires in March 2029. The defendants named in the lawsuit include Sun Pharma Global FZE, Teva Pharmaceuticals USA, Inc., Wockhardt Bio AG, and related companies and subsidiaries. Forest received notification from those companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of NAMENDA XR before the expiration of some or all of the Patents. The lawsuit was commenced before the expiration of forty-five days from the date of receipt of each notification letter, which triggered an automatic stay of approval of the applicable ANDAs that expires no earlier than June 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WBIO:SW SFr.2.51 CHF 0.00

WBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation WBIO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 3.8x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT BIO AG-BR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at